Horus Pharma is a revenue-generating, private French biopharmaceutical company with a strong focus on ophthalmology and dermatology. The company has demonstrated consistent growth, reporting €93 million in turnover for 2023, driven by a diversified portfolio and international expansion. Its strategy is built on innovation in preservative-free formulations, a commitment to high ethical standards, and a dynamic European commercial footprint.
OphthalmologyDermatology
Technology Platform
Expertise in developing and formulating preservative-free ophthalmic and dermatological products, including medicinal products, medical devices, and supplements.
Funding History
1
Total raised:$10M
Series A$10MUndisclosed
Opportunities
Significant growth opportunity lies in expanding its European footprint and entering new international markets like North America or Asia.
The growing demand for preservative-free ophthalmic products and the expansion into surgical/diagnostic devices provide adjacent market opportunities.
The dermatology segment offers another avenue for applying its formulation expertise.
Risk Factors
Faces intense competition from large multinational pharmaceutical companies with greater resources.
Growth is dependent on the successful execution of international expansion, which carries operational and regulatory risks.
The company's value proposition is closely tied to the preservative-free niche, which could be eroded by competitor actions or shifting clinical perspectives.
Competitive Landscape
Operates in the highly competitive European ophthalmology market, competing against giants like Novartis/Alcon, AbbVie/Allergan, and Bausch + Lomb, as well as other specialized laboratories. Its primary differentiation is its focus and expertise in preservative-free formulations, a niche where it has established early leadership.
